Global biotechnology company Biogen Idec and Abbott Laboratories have announced positive results from its multiple sclerosis drug daclizumab HYP.

Results of the SELECT Phase 2b trial showed that the once-monthly drug reduced annual relapse rates by 54% in the 150mg dose arm and by 50% in the 300mg dose arm.

Findings also showed that DAC HYP reduced the risk of sustained disability progression by 57% in the 150mg dose arm and by 43% in the 300mg dose arm compared to a placebo.

Abbott vice president for global pharmaceutical clinical development, Eugene Sun, said: “These results bring us one step closer in the development of a potential new treatment option for multiple sclerosis, an area of medicine where there continues to be a significant need for novel approaches for patients.

“We look forward to continued analysis of the SELECT data and the opportunity to present these results in full context at an upcoming scientific forum.”